Livostor

Prevention of cardiovascular diseases.

In adult patients without clinically evident coronary heart disease, but with several risk factors for coronary heart disease, such as age, smoking, hypertension, low HDL cholesterol, or a family history of early coronary heart disease, Livostor is indicated for:

• reducing the risk of myocardial infarction;
• reducing the risk of stroke;
• reducing the risk of angina and revascularisation procedures.

In patients with type II diabetes mellitus and without clinically evident coronary heart disease, but with several risk factors for coronary heart disease, such as retinopathy, albuminuria, smoking, or hypertension, Livostor is indicated for:

• reducing the risk of myocardial infarction;
• reducing the risk of stroke.

In patients with clinically evident coronary heart disease, Livostor is indicated for:

• reducing the risk of non-fatal myocardial infarction;
• reducing the risk of fatal and non-fatal stroke;
• reducing the risk of revascularisation procedures;
• reducing the risk of hospitalisation due to congestive heart failure; – reducing the risk of angina pectoris.

Hyperlipidaemia

• As a dietary supplement to reduce elevated levels of total cholesterol, LDL cholesterol, apolipoprotein B and triglycerides, as well as to increase HDL cholesterol levels in patients with primary hypercholesterolemia (heterozygous familial and non-familial) and mixed dyslipidemia (Fredrickson types IIa and IIb).
• As an adjunct to a diet for the treatment of patients with elevated serum triglyceride levels (Fredrickson type IV). – For the treatment of patients with primary dysbetalipoproteinemia (Fredrickson type III) in cases where dietary compliance is not effective enough.
• To reduce total cholesterol and LDL cholesterol in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatments (e.g. LDL apheresis), or if such treatments are not available.
• As an adjunct to a diet to reduce total cholesterol, LDL cholesterol and apolipoprotein B in boys and girls after the onset of menstruation, aged 10 to 17 years with heterozygous familial hypercholesterolemia, if, after appropriate dietary therapy, the test results are as follows:
  a) LDL cholesterol remains 190 mg/dL or
  b) LDL cholesterol remains 160 mg/dL and:
  • • there is a family history of early cardiovascular disease
    • or the patient has two or more other risk factors for cardiovascular disease in childhood.